Mylan MYL

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Mylan launches generic version of Klor-Con

      Headlines

      Fri, 22 Aug 2014

      Mylan (NASDAQ: MYL ) begins shipping its potassium chloride extended release tablets (8 mEq (600 mg) and 10 mEq (750 mg)), generic versions

    2. Not so fast, Mylan

      Headlines

      Wed, 20 Aug 2014

      0.3% ) intervened on Hospira's behalf because the ruling would deprive it of the six-month exclusivity it negotiated in its patent infringement settlement with Hospira in December. Related ticker: ( MYL +2.8% ) Post your comment!

    3. Mylan launches generic version of Precedex

      Headlines

      Tue, 19 Aug 2014

      After the FDA approved its ANDA yesterday, Mylan ( MYL +1.3% ) launches dexmedetomidine hydrochoride injection ..... 2.8% ) Precedex . The U.S. market is ~$156M. Mylan has 295 ANDAs pending FDA approval representing ~$105B

    4. Why Tax Inversions Won't Go Away

      Headlines

      Wed, 13 Aug 2014

      PRGO ) acquiring Elan Pharmaceuticals of Ireland Mylan Laboratories (NASDAQ: MYL ) acquiring an Abbott Laboratories (NYSE: ABT ) subsidiary to move to the Netherlands Mylan getting rejected by Meda (MEDAA) Complete Story

    5. New Morningstar Analyst Report for Mallinckrodt PLC

      Stock Reports

      Wed, 13 Aug 2014

      While we believe an acquisition is possible, we would caution against investors speculating on a takeover, given that Mylan /Abbott and Salix/Cosmo have recently shown the market ways to drastically lower tax rates without acquiring an Irish

    6. The Long Case For Mylan

      Headlines

      Mon, 11 Aug 2014

      By MYL ) by downgrading price targets for the year ..... of 20% compared to their current 35%. Mylan remains deal hungry and has the balance sheet ..... is a buyers market. Company Description Mylan is one of the world's largest pharmaceutical

    7. New Morningstar Analyst Report for Actavis PLC

      Stock Reports

      Fri, 8 Aug 2014

      marks for shareholder stewardship. Historically, Actavis has avoided an aggressive acquisition strategy like Teva and Mylan , but management has proved adept at finding niche generic opportunities, including Lipitor, Lovenox, and Concerta, which

    8. UPDATE 2- Mylan presses on with tax-inversion Abbott deal

      Headlines

      Thu, 7 Aug 2014

      * CEO: Tax-inversion deals do not stop companies paying US taxes

    9. Mylan's ( MYL ) CEO Heather Bresch on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 7 Aug 2014

      Mylan (NASDAQ: MYL ) Q2 2014 Earnings Call August 07, 2014 10:00 am ET Executives Kris King - Heather Bresch - Chief Executive Officer, Director

    10. Mylan updates guidance after Q2 results

      Headlines

      Thu, 7 Aug 2014

      Mylan ( MYL -1.2% ) Q2 results : Revenues: $1,837.3M (+8.0%); Gross Profit: $808.8M (+8.9%); Operating Expenses

    « Prev12345Next »
    Content Partners